Copyright
©The Author(s) 2022.
World J Gastroenterol. Apr 7, 2022; 28(13): 1347-1361
Published online Apr 7, 2022. doi: 10.3748/wjg.v28.i13.1347
Published online Apr 7, 2022. doi: 10.3748/wjg.v28.i13.1347
Characteristics | Primary training cohort (%) | Internal validation cohort (%) | External validation cohort (%) |
Total | 175 (61.2) | 111 (38.8) | 85 (100) |
Diagnose age | |||
< 50 | 21 (12.0) | 16 (14.4) | 10 (11.8) |
50-60 | 59 (33.7) | 47 (42.3) | 35 (41.2) |
> 60 | 95 (54.3) | 48 (43.2) | 40 (47.1) |
Age | 61.35 ± 7.99 | 60.25 ± 7.97 | 60.15 ± 8.50 |
Incidence area | |||
High | 138 (78.9) | 89 (80.2) | 64 (75.3) |
Low | 37 (21.1) | 22 (19.8) | 21 (24.7) |
Tumor location | |||
Upper | 34 (19.4) | 19 (17.1) | 11 (12.9) |
Middle | 113 (64.6) | 79 (71.2) | 66 (77.6) |
Lower | 28 (16.0) | 13 (11.7) | 8 (9.4) |
Differentiation | |||
Higher | 11 (6.3) | 8 (7.2) | 3 (3.5) |
Moderate | 101 (57.7) | 67 (60.4) | 51 (60.0) |
Lower | 63 (36.0) | 36 (32.4) | 31 (36.5) |
T stage | |||
T1/T2 | 64 (36.6) | 32 (28.8) | 26 (30.6) |
T3/T4 | 111 (63.4) | 79 (71.2) | 59 (69.4) |
N stage | |||
N0 | 86 (49.1) | 60 (54.1) | 46 (54.1) |
N1-N3 | 89 (50.9) | 51 (45.9) | 39 (45.9) |
Therapy methods | |||
Operation | 164 (93.7) | 106 (95.5) | 82 (96.5) |
Others | 11 (6.3) | 5 (4.5) | 3 (3.5) |
Family history | |||
No | 116 (66.3) | 66 (59.5) | 56 (65.9) |
Yes | 59 (33.7) | 45 (40.5) | 29 (34.1) |
ESR1 | |||
Negative | 49 (28.0) | 41 (36.9) | 29 (34.1) |
Positive | 126 (72.0) | 70 (63.1) | 56 (65.9) |
ESR2 | |||
Negative | 63 (36.0) | 39 (35.1) | 24 (28.2) |
Positive | 112 (64.0) | 72 (64.9) | 61 (71.8) |
Menarche age | |||
< 14 | 28 (16.0) | 23 (20.7) | 12 (14.1) |
14-16 | 85 (48.6) | 45 (40.5) | 41 (48.2) |
> 16 | 62 (35.4) | 43 (38.7) | 32 (37.6) |
Menopausal age | |||
< 46 | 48 (27.4) | 19 (17.1) | 23 (27.1) |
46-55 | 47 (26.9) | 36 (32.4) | 20 (23.5) |
> 55 | 80 (45.7) | 56 (50.5) | 42 (49.4) |
Pregnancy number | |||
< 4 | 61 (34.9) | 40 (36.0) | 30 (35.3) |
4-6 | 86 (49.1) | 52 (46.8) | 43 (50.6) |
> 6 | 28 (16.0) | 19 (17.1) | 12 (14.1) |
Primary training set | Internal validation set | External validation set | ||||
C-index (95%CI) | P value | C-index (95%CI) | P value | C-index (95%CI) | P value | |
Full model | 0.701 (0.655-0.746) | Ref. | 0.684 (0.619-0.748) | Ref. | 0.672 (0.609-0.734) | Ref. |
Clinical-model | 0.629 (0.578-0.681) | 0.000 | 0.593 (0.531-0.655) | 0.009 | 0.589 (0.514-0.663) | 0.014 |
TNM stage | 0.638 (0.576-0.699) | 0.013 | 0.552 (0.462-0.641) | 0.011 | 0.560 (0.462-0.657) | 0.033 |
- Citation: Zhang DY, Ku JW, Zhao XK, Zhang HY, Song X, Wu HF, Fan ZM, Xu RH, You D, Wang R, Zhou RX, Wang LD. Increased prognostic value of clinical–reproductive model in Chinese female patients with esophageal squamous cell carcinoma. World J Gastroenterol 2022; 28(13): 1347-1361
- URL: https://www.wjgnet.com/1007-9327/full/v28/i13/1347.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i13.1347